Liver cancer trial tests combo therapy against single drug

NCT ID NCT07408804

Recruiting now Disease control Sponsor: Bangladesh Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a targeted chemotherapy procedure (TACE) to the drug lenvatinib works better than lenvatinib alone for people with liver cancer that cannot be removed by surgery. About 40 adults with early to advanced liver cancer will be enrolled. The goal is to see if the combination shrinks tumors more effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Hepatology, Bangladesh Medical University
RECRUITING

Dhaka, 1000, Bangladesh

Contact Phone: •••-•••-••••

Contact Phone: •••-•••-•••• Email: •••••@•••••